Medtronic's stent for twisted arteries cleared:
This article was originally published in Clinica
Executive Summary
Medtronic has received clearance from the FDA to market a new stent for supporting the heart's more tortuous arteries. The Wiktor Rival system is for treating abrupt or threatened vessel closure in patients with failed interventional therapy or suboptimal percutaneous transluminal coronary angioplasty. The device, which was granted a PMA supplement, has low deployment and post-deployment pressures to protect vessel tissue and eliminate the need for high-pressure balloon catheters, which are time consuming to use and add to cost.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.